A Randomized Trial of Maintenance Therapy for Vasculitis Associated with Antineutrophil Cytoplasmic Autoantibodies
- 3 July 2003
- journal article
- clinical trial
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 349 (1), 36-44
- https://doi.org/10.1056/nejmoa020286
Abstract
The primary systemic vasculitides usually associated with autoantibodies to neutrophil cytoplasmic antigens include Wegener's granulomatosis and microscopic polyangiitis. We investigated whether exposure to cyclophosphamide in patients with generalized vasculitis could be reduced by substitution of azathioprine at remission.Keywords
This publication has 38 references indexed in Scilit:
- Renal histology in ANCA-associated vasculitis: Differences between diagnostic and serologic subgroupsKidney International, 2002
- The value of pulse cyclophosphamide in ANCA‐associated vasculitis: meta‐analysis and critical reviewNephrology Dialysis Transplantation, 2001
- Evidence‐based treatment of systemic vasculitisRheumatology, 2000
- Kidney biopsy as a predictor for renal outcome in ANCA-associated necrotizing glomerulonephritisKidney International, 1999
- Relationship between disease activity and anti-neutrophil cytoplasmic antibody concentration in long-term management of systemic vasculitisAmerican Journal of Kidney Diseases, 1995
- Nomenclature of Systemic VasculitidesArthritis & Rheumatism, 1994
- Short form 36 (SF36) health survey questionnaire: normative data for adults of working age.BMJ, 1993
- The MOS 36-ltem Short-Form Health Survey (SF-36)Medical Care, 1992
- Wegener Granulomatosis: An Analysis of 158 PatientsAnnals of Internal Medicine, 1992
- Cyclophosphamide Therapy of Severe Systemic Necrotizing VasculitisThe New England Journal of Medicine, 1979